Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Enterprise Value (2017 - 2025)

Inmune Bio (INMB) has disclosed Enterprise Value for 9 consecutive years, with -$24.8 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 18.3% to -$24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.8 million through Dec 2025, down 18.3% year-over-year, with the annual reading at -$24.8 million for FY2025, 18.3% down from the prior year.
  • Enterprise Value hit -$24.8 million in Q4 2025 for Inmune Bio, up from -$27.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$19.3 million in Q1 2025 to a low of -$84.5 million in Q3 2021.
  • Historically, Enterprise Value has averaged -$43.7 million across 5 years, with a median of -$40.7 million in 2021.
  • Biggest five-year swings in Enterprise Value: tumbled 720.6% in 2021 and later soared 49.02% in 2024.
  • Year by year, Enterprise Value stood at -$74.8 million in 2021, then skyrocketed by 30.29% to -$52.2 million in 2022, then surged by 31.26% to -$35.8 million in 2023, then surged by 41.64% to -$20.9 million in 2024, then decreased by 18.3% to -$24.8 million in 2025.
  • Business Quant data shows Enterprise Value for INMB at -$24.8 million in Q4 2025, -$27.7 million in Q3 2025, and -$33.4 million in Q2 2025.